Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 461 Melanoma 300 Squamous Cell Carcinoma of Head and Neck 234 Parkinson Disease 4, Autosomal Dominant Lewy Body 189 Neoplasms 185 Breast Neoplasms 162 Triple Negative Breast Neoplasms 161 Neoplasm Metastasis 156 Lung Neoplasms 146 Colorectal Neoplasms 142 Carcinoma, Renal Cell 132 Head and Neck Neoplasms 123 Stomach Neoplasms 104 Ovarian Neoplasms 100 Carcinoma, Transitional Cell 91 Urinary Bladder Neoplasms 81 Pancreatic Neoplasms 81 Carcinoma, Hepatocellular 74 Endometrial Neoplasms 72 Uterine Cervical Neoplasms 63 Esophageal Neoplasms 57 Recurrence 52 Prostatic Neoplasms 49 Sarcoma 43 Carcinoma 42 Glioblastoma 40 Carcinoma, Squamous Cell 39 Small Cell Lung Carcinoma 38 Hodgkin Disease 36 Cholangiocarcinoma 35

Interventions

enzalutamide 5 abiraterone 2 Radiotherapy 2 Metastasectomy 2 Abiraterone Acetate 2 testosterone enanthate 1 radium Ra 223 dichloride 1 pembrolizumab 1 disitamab vedotin 1 dactolisib 1 VT-464 1 Radium-223 1 Radiosurgery 1 Prednisone 1 NVP-BKM120 1 Ketoconazole 1 Injections 1 Hydrocortisone 1 Flutamide 1 Cyclophosphamide 1 Crizotinib 1 Control Groups 1 Carboplatin 1 Calcitriol 1 Blood Specimen Collection 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Castration-resistant Prostate Cancer × pembrolizumab × Clear all

NCT03506997 2020-07-22

PERSEUS1

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡